Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

NCT00865605 | Completed Phase 1

• 1 other identifier: DP03-689
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.).

Conditions

Healthy

Keywords

bioequivalence; Vasoconstriction; Halobetasol; Healthy subjects

Outcome Measures

Primary Outcomes (1)

• Primary outcome: Vasoconstrictor Response

  36 hours

Study Arms (2)

A

EXPERIMENTAL

Halobetasol Propionate 0.05% Ointment, single exposure

Drug: Halobetasol Propionate 0.05% Ointment, single exposure

B

ACTIVE COMPARATOR

Ultravate® 0.05% ointment, single exposure

Drug: Ultravate® 0.05% ointment, single exposure

Interventions

Halobetasol Propionate 0.05% Ointment, single exposure DRUG

A: Other Subjects received Alpharma/Purepac USHP formulated products

Also known as: Halobetasol

A

Ultravate® 0.05% ointment, single exposure DRUG

Subjects received Bristol-Myers Squibb Company formulated products

Also known as: Halobetasol

B

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject understands the study, is willing to participate, and gives written informed consent.
• Subject demonstrates adequate vasoconstriction to the screening topical corticosteroid Halobetasol propionate 0.05% ointment within 30 days of dosing.
• Subject is a non-smoking (minimum of 14 days), male or female, ages of 18 - 65 years, inclusive.
• Subject is within 20% of their ideal body weight as defined by the 1999 Metropolitan Life Insurance Company Height and Weight Tables.
• Subject is judged by the Investigator to be healthy on the basis of pre-study medical history.
• Subjects of child-bearing potential agree to use an acceptable method of birth control during study participation (e.g. abstinence, any prescribed birth control method, double barrier method, Le. condom plus foam, condom plus diaphragm).
• Subject is willing to refrain from excessive consumption of sodium in food or beverage 48hrs before and for the duration of the study.
• Subject is willing to shower using the same soap/cleansers for the duration of the study.
• Subject is willing to follow study restrictions.

You may not qualify if:

• Subject has a past or current medical condition that might significantly affect pharmacodynamic response to topical corticosteroids.
• Subject has diabetes mellitus, clinically significant hypertension or circulatory disease.
• Subject is taking any medication on a regular basis that could modulate blood flow (constrictor or dilator), with the exception of any prescribed birth control method and hormone replacement therapy. Examples of such drugs include nitroglycerin, anti- hypertensives, antihistamines, NSAIDs, aspirin, phenylpropanolamine, phentolamine or any other medications deemed inappropriate by the Investigator.
• Subject intends to start, stop or change dose of any prescription or OTC medication within 48 hours prior to or throughout the study. Acetaminophen may be administered, if needed.
• Subject has used prescription or OTC topical medications on the ventral forearms within 1 month prior to study conduct.
• Subject has a history of sensitivity/allergy to the ingredients found in the test formulations or has a history of adverse reactions to topical or systemic corticosteroids.
• Subject has a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
• Subject has a history of significant skin conditions or disorders, for example, psoriasis, atopic dermatitis, etc.
• Subject has a history of significant dermatologic cancers, for example, melanoma or squamous cell carcinoma. Basal cell carcinomas that were superficial and do not involve the investigative site are acceptable.
• Subject has an obvious difference in skin color between arms or the presence of a skin condition, scar tissue, tattoo or coloration that would interfere with placement of test sites, their assessments, their reaction to drug or could compromise the safety of the subject.
• Subject has used topical medications on the ventral forearms within 1 month prior to dosing.
• Subject has used a tobacco product within 14 days of study conduct.
• Subject has a clinically significant history of drug abuse or alcoholism.
• Subject has donated or received blood within 30 days prior to dosing.
• Subject's caffeine intake is greater than 500 mg per day (1 cup of coffee contains approximately 85 mg of caffeine).

Sponsors & Collaborators

• Actavis Inc.: lead

Study Sites (1)

DermTech International

San Diego, California, 92128, United States

Location

MeSH Terms

Interventions

halobetasol; Ointments

Intervention Hierarchy (Ancestors)

Dosage Forms; Pharmaceutical Preparations

Study Officials

• Paul A. Lehman,, M.Sc.

  DermTech International

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: March 17, 2009
• First Posted: March 19, 2009
• Study Start: December 1, 2003
• Primary Completion: July 1, 2004
• Study Completion: July 1, 2004
• Last Updated: August 17, 2010

Record last verified: 2010-08

Locations

US (1)